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A Case of Fabry’s Disease with Congenital Agammaglobulinemia
Fabry’s disease is an X-linked lysosomal storage disorder caused by abnormalities in the 
α-galactosidase A (GLA) gene, which leads to a GLA deficiency and to the intracellular 
deposition of globotriaosylceramide (Gb3) within vascular endothelium and other tissues. 
It manifests as progressive multiple organ dysfunctions caused by the deposition of Gb3. 
On the other hand, congenital agammaglobulinemia is usually caused by mutations in 
Bruton’s tyrosine kinase (Btk) gene with X-linked dominence, suppresses B cell maturation, 
and causes recurrent pyogenic infections. In former reports, the distance between the loci 
in the Xq22 region of the human X chromosome was found to be about 69 kilobases. A 
23-yr-old man diagnosed with congenital agammaglobulinemia at age 5, showed typical 
clinical and laboratory and histopathological findings of Fabry’s disease. The genetic basis 
of this combination of the two syndromes was studied in this patient. Here, we report a 
case of Fabry’s disease with congenital agammaglobulinemia.
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CASE REPORT
Dermatology
INTRODUCTION
Fabry’s disease, sometimes referred to as Anderson-Fabry dis-
ease, is a rare X-linked disorder caused by deficient activity of 
the lysosomal enzyme, α-galactosidase A (GLA), and the progres-
sive accumulation of glycosphingolipid globotriaosylceramide 
(Gb3) in various organ systems (1, 2). Fabry’s disease is charac-
terized clinically by chronic pain and acroparesthesia, gastroin-
testinal disturbances, characteristic skin lesions (angiokerato-
ma), progressive renal impairment, cardiomyopathy, and stroke. 
The causative gene, the so-called GLA gene, is located on the X-
chromosome at q22.1, and more than 150 mutations of this gene 
have been detected (3). On the other hand, congenital agamma-
globulinemia is a rare genetic disorder characterized by a dra-
matically reduction or absence of mature B lymphocytes in pe-
ripheral blood (usually < 2% of total lymphocytes), caused by 
differentiation arrest affecting the transition of B-cell progeni-
tors into mature B lymphocytes (4). The Bruton tyrosine kinase 
(Btk) gene, located in the Xq21.3-q22 region at the long arm of 
chromosome X, has been shown to be the major causative gene 
of congenital agammaglobulinemia (5).
  Both Fabry’s disease and congenital agammaglobulinemia are 
rare genetic disorders, and to our knowledge, no case of Fabry’s 
disease and congenital agammaglobulinemia co-occurrence 
has previously been reported. Here, we describe the case of a 
Korean man with both syndromes.
CASE DESCRIPTION
A 23-yr-old Korean man presented with multiple tiny red to pur-
ple papules on his back and scrotum. Although he first noticed 
the lesions 5 yr previously, he has received no treatment. Prior 
to presentation, he had noticed that the numbers were increas-
ing, and thus, he visited our dermatology department for evalu-
ation and work-up on 13 October 2008. 
  He had been on immunoglobulin replacement (IVIG 300-400 
mg/kg monthly) therapy since he had received a diagnosis of 
congenital agammaglobulinemia at 5 yr. Furthermore, he had a 
history of recurrent respiratory infections, acroparesthesia, and 
hypohidrosis from childhood, and had presented with persis-
tent and progressive proteinuria from 14 yr. 
  The patient was born to nonconsanguineous parents and there 
was no familial history. A physical examination revealed multi-
ple 2-4 mm sized, red to purple papules on his back and scro-
tum (Fig. 1A, B). Neurologic examination results were normal 
aside except for patchy temperature sensation impairment on 
the lower legs and feet. 
  Skin biopsies of the angiomatous lesions on his back and scro-
tum, commonly showed dilated capillaries in the papillary der-
mis and sometimes vacuoles within endothelial cells (Fig. 1C, 
D). Complete blood count, electrolytes, complements, and liver, 
kidney, and thyroid function tests were non-specific. However, 
an immunoglobulin series revealed that almost all immunoglob-
ulins, except IgD and IgG, were much reduced; immunoglobu-Lee K-Y, et al.  •  Fabry’s Disease with Congenital Agammaglobulinemia
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Fig. 1. Clinical features and histopathologic findings. Multiple tiny red papules on (A) back and (D) scrotum. A skin biopsy from (B&C) back and (E&F) scrotum showed capillary 
dilatation on papillary dermis and several vacuolar changes in endothelial cells.
A C B
Fig. 2. A renal biopsy revealed (A) global sclerosis and segmental sclerosis with moderate interstitial fibrosis (H&E, × 20) and (B&C) diffuse foamy changes of podocyte and tu-
bular epithelial cell cytoplasm (H&E, × 400).
lin replacement therapy had probably resulted a near normal 
IgG level (802 mg/dL, ref.: 880-1,800 mg/dL). 
  Furthermore, the B cell percentage was markedly lower at < 
0.1% by lymphocyte analysis, and proteinuria (random urine P/
Cr = 3.94 g/g, microalbumin > 500 μg/mL, 24-hr urine protein 
excretion = 3.192 g) was still evident. Electrocardiography find-
ings suggested left ventricular hypertrophy. Renal ultrasono-
graphic findings were normal, but a histopathologic examina-
tion of a kidney specimen showed global and segmental sclero-
sis in glomeruli with moderate fibrosis in interstitia, and diffuse 
foamy changes within the cytoplasm of podocytes and tubular 
epithelial cells (Fig. 2). Electron microscopic findings showed 
numerous electron dense lamellar inclusion bodies (Gibra bod-
ies) in the cytoplasm of skin fibroblasts and renal podocytes (Fig. 
3). On ophthalmologic evaluation revealed the presence of fine, 
whorl-like superficial corneal opacities, and vertex dystrophy 
(Fig. 4).
  A GLA enzyme activity assay showed 105 nmole/hr/μg (nor-
mal control: 2,744), representing a reduction to only 4% of nor-
mal. We received a written consent from his parents and per-
formed the genetic analysis. DNA PCR-sequence analysis iden-
tified an intronic variation on the splicing acceptor site in the Lee K-Y, et al.  •  Fabry’s Disease with Congenital Agammaglobulinemia
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Fig. 3. Electron microscopic findings. (A) Numerous electron dense lamellar inclusion bodies in the cytoplasm of skin fibroblasts (skin) and (B&C) renal podocytes (kidney).
Fig. 4. Slit-lamp finding showed fine, whorl-like, superficial corneal opacities.
GLA gene (Fig. 5A), and direct sequencing studies of peripheral 
blood DNA identified the presence of a GLA gene mutation (Fig. 
5B) but revealed no genetic abnormality at the Btk gene locus, 
which is shown by 85% of patients with congenital agammaglob-
ulinemia. As a result of these clinical and laboratory findings, 
he has diagnosed as having both Fabry’s disease and non-Bru-
ton type congenital agammaglobulinemia. He is being treated 
with intravenous gammaglobulin (400 mg/kg) monthly for the 
congenital agammaglobulinemia and with oral ACE inhibitors 
for proteinuria. GLA enzyme replacement therapy is planned 
to treat Fabry’s disease. 
DISCUSSION
Fabry’s disease is an X-linked metabolic disorder that was initial-
ly described in 1898. The incidence of Fabry’s disease has been 
estimated at one per 40,000 to 117,000 worldwide (6). Deficien-
cy of GLA leads to the storage of neutral glycosphingolipids, par-
ticularly of Gb3, in many tissues and cell types. The progressive 
accumulation of these molecules eventually leads to cellular dys-
Marker Normal Patient
A B
Fig. 5. DNA analysis. (A) The PCR results showing 
smaller size at DNA PCR for GLA cDNA compared 
with normal control. (B) DNA sequence analysis show-
ing c.640-11T>A on intron 4 which is the splicing 
acceptor site in the GLA gene.
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function, and possibly to inflammation and/or fibrosis. These 
processes lead to organ dysfunction and clinical evidence of Fab-
ry’s disease. The mechanism of tissue damage is believed to be 
at least partly due to poor perfusion caused by accumulations 
in the vascular endothelium, particularly in kidneys, heart, the 
nervous system, and skin either alone or in combination with 
deposits in other cell types (2). 
  The progression of clinical symptoms in Fabry’s disease can 
be considered conceptually to follow patient age. Early symp-
toms in children include acroparesthesia, hypohidrosis, and gas-
trointestinal symptoms, such as, nausea, abdominal pain, and 
postprandial diarrhea (7, 8). However, from age 20 yr, these symp-
toms tend to progress and proteinuria appear. Renal failure is 
usually encountered in most men with the disease with concom-
itant progression in other affected organ systems, which leads 
to life-threatening cardiac and cerebrovascular manifestations 
and substantial morbidity (8). 
  The GLA gene, the causative gene of Fabry’s disease, is locat-
ed in the Xq22.1 region. It is about 12 kb long and contains 7 ex-
ons that encode a precursor protein of 429 amino acids. The ba-
sic molecular defects in Fabry disease include partial deletion, 
duplication, and point mutation of the GLA gene (9). Currently, 
more than 400 mutations have been detected in this gene. 
  Congenital agammaglobulinemia is a rare humoral immuno-
deficiency disease. The prevalence of congenital agammaglob-
ulinemia has been estimated at one per 200,000 worldwide (10). 
Affected individuals have markedly reduced levels of all major 
classes of immunoglobulins in serum, and increased suscepti-
bility to recurrent bacterial infections (11-13). The most com-
mon symptoms of congenital agammaglobulinemia are sinus-
itis, bronchitis, otitis, and pneumonia, and symptoms usually 
appear in infancy or early childhood after maternal immuno-
globulins have been lost. Approximately 85% of patients with 
congenital agammaglobulinaemia have the X-linked form due 
to mutations in the Btk gene (12). The remaining 15% of cases, 
which clinically are inseparable from X-linked agammaglobu-
linemia cases, have an autosomal recessive or idiopathic form. 
  The Btk gene, the most common causative gene of congenital 
agammaglobulinemia, is located in the Xq21.3-q22 region, and 
was first identified in 1993 (13). It spans 37.5 kb of genomic DNA, 
consists of 19 exons (14), and encodes a 77 kDa cytoplasmic pro-
tein tyrosine kinase containing five domains, that is, the N-ter-
minal pleckstrin homology (PH), the proline-rich Tec homolo-
gy (TH), the Src homology 3 (SH3), the Src homology 2 (SH2), 
and the catalytic tyrosine kinase (TK) domains (15). Btk is ex-
pressed by all hematopoietic lineages, excepting T lymphocytes 
and plasma cells, and plays an essential role in the development 
of B cells. Our ability to identify Btk gene mutations probably ex-
plains why X-linked agammaglobulinemia is the most common-
ly diagnosed type of congenital agammaglobulinemia, and to 
date more than 600 unique Btk gene mutations have been re-
corded in the BTKbase (a designated international mutation 
database) (10). 
  The described case had symptoms and signs typical of both 
Fabry’s disease and congenital agammaglobulinemia, respec-
tively. Several disease clusters are located around loci in the Xq22 
region, such as, those of Alport syndrome, Fabry’s disease, and 
X-linked agammaglobulinemia. In 1995, Oeltjen et al. (16) re-
ported that the Btk gene and the GLA gene are localized in the 
same 50 to 70 kb region. However, the relationships between 
genes in this region have not established despite their contigui-
ties. A genetic study was undertaken to detect GLA and Btk genes 
abnormalities in present case to investigate whether the co-oc-
currence of the two syndromes was incidental or inevitable. How-
ever, we were unable to find any abnormality in the Btk gene or 
any specific genetic relationship between the two disorders, and 
thus, it appears that their co-occurrence in our patient was co-
incidental. 
  Here, we report the first case of Fabry’s disease with congeni-
tal agammaglobulinemia in 23-yr-old man. Although we were 
unable to find any abnormality in the Btk gene or any specific 
genetic relationship between the two disorders, this case pro-
vided a rare and interesting opportunity to consider these two 
syndromes on a genetic basis. It is suggested that more genetic 
studies should be performed to identify the association between 
Fabry’s disease and congenital agammaglobulinemia. 
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